FDA Approves Daraxonrasib, a New Drug for Pancreatic Cancer, Doubling Survival

The FDA has approved daraxonrasib, a new drug for pancreatic cancer that targets a mutated protein fueling tumor growth. In trials, the drug roughly doubled survival rates compared to standard chemotherapy for previously treated patients.